Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021
Five of six mTOR inhibitor-naïve patients with TSC1 or TSC2 inactivating alterations achieved confirmed partial responses to single-agent FYARROTumor-agnostic registrational trial of FYARRO in mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 inactivating alterations to be initiated by the end of 2021 LOS ANGELES, June 04, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined ca
Source: yahoo.com